Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Archives

2016 News Releases

December 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
Ticker symbol to remain PBYI
Read

December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

Caligor Opco LLC to provide regulatory, logistical and supply chain support Read

November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results
Read

October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock
Read

October 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share
Read

October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock
Read

October 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock
Read

September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results
Read

July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Read

July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Read

June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
Read

May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
Read

May 17, 2016 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read

May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results
Read

May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read

Apr. 20, 2016 - Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016
Read

Apr. 14, 2016 - Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology
Read

Mar. 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016
Read

Mar. 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
Read

Mar. 2, 2016 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read

Feb. 29, 2016 - Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results
Read

Feb. 17, 2016 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
Read

Feb. 16, 2016 - Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation
Read

Feb. 11, 2016 - Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology
Read

Feb. 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference
Read

Jan. 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation
Read

Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read



2015 News Releases

Dec. 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea
Read

Dec. 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer
Read

Nov. 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency
Read

Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results
Read

Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
Read

Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation
Read

Aug. 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results
Read

June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference
Read

June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Read

May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference
Read

May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Read

May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference
Read

May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results
Read

May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read

April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference
Read

April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Mar. 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Read

Mar. 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Read

Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference
Read

Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference
Read

Jan. 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Read

Jan. 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
Read

Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Jan. 20, 2015 - Puma Biotechnology Announces Proposed Public Offering
Read

Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read



2014 News Releases

Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium

Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read

Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application
-NDA Filing Currently Anticipated for Q1 2016
Read

Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Read

Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference
Read

Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results
Read

Sept. 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Read

Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Read

Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results
Read

July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
Read

July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer
Read

June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Read

June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting
Read

May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference
Read

May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read

May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Read

May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results
Read

May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Read

Apr. 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Read

Mar. 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference
Read

Mar. 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014
Read

Mar. 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results
Read

Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read

Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Read

Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Feb. 6, 2014 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Read



2013 News Releases

Dec. 17, 2013 - Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations Read

Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL
Neratinib Graduates from I-SPY 2 TRIAL Read

Nov. 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read

Oct. 4, 2013 - Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read

Sept. 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read

Aug. 6, 2013 - Puma Biotechnology Reports Second Quarter 2013 Financial Results Read

June 24, 2013 - Puma Biotechnology to Join Russell 3000 Index Read

June 7, 2013 - Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read

June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read

May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read

May 17, 2013 - Puma Biotechnology Comment on Trading Activity Read

May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read

May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read

May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read

April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read

Feb. 26, 2013 - Puma Biotechnology to Present at Cowen Health Care Conference Read

Feb. 20, 2013 - Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read

Feb. 6, 2013 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read



2012 News Releases

December 7, 2012 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read

Nov. 14, 2012 - Puma Biotechnology Reports Third Quarter 2012 Financial Results
Read

Nov. 7, 2012 - Puma Biotechnology to Present at Lazard Healthcare Conference
Read

October 24, 2012 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read

October 22, 2012 - Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million
Read

October 18, 2012 - Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock
Read

September 12, 2012 - Puma Biotechnology to Present at UBS Global Life Sciences Conference
Read

August 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference
Read

August 14, 2012 - Puma Biotechnology Reports Second Quarter 2012 Financial Results
Read

August 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference
Read

June 2, 2012 - Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting
Phase I Results Demonstrate Safety and Efficacy of PB272 in Combination with Paclitaxel and Trastuzumab in Women with Metastatic HER-2 Positive Breast Cancer
Read

May 30, 2012 - Puma Biotechnology to Present at Jefferies Healthcare Conference
Read

May 17, 2012 - Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting
Read

May 9, 2012 - Puma - Merrill Lynch Health Care Conference
Read

April 16, 2012 - Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK
Read

February 28, 2012 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

February 9, 2012 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference
Read

January 4, 2012 - Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference
Read



2011 News Releases

December 9, 2011 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Read

November 23, 2011 - Puma Biotechnology Announces Completion of Private Placement Raises second tranche of capital bringing total offering proceeds to $60 Million
Read

October 5, 2011 - Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational PanHER Inhibitor; Closes $55 Million Private Placement and Completes Merger
Read



Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

info@pumabiotechnology.com